XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

X4 Pharmaceuticals, Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$2.75+0.16 (+6.18%)

Close on Oct 19, 2026

Market cap: $347.45M
P/E (TTM): –
Dividend yield: –

X4 Pharmaceuticals, Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	6.50	2.60	0	0	0	3.00	0	0	–	–
Cost of Revenue	5.76	0.80	0	0	–	–	–	–	–	–
Gross Profit	0.74	1.80	0	0	–	–	–	–	–	–
Research & Development	73	82	72	61	51	42	30	20	17	18
General & Administrative	44	62	36	27	25	21	18	8.74	5.18	6.52
Operating Expenses	–	–	108	88	85	63	52	29	22	24
Total Costs & Expenses	–	39	108	88	–	–	–	–	–	–
Operating Income	-87	-36	-108	-88	-85	-60	-52	-29	-22	-24
Interest Expense	8.88	8.77	5.78	3.99	3.64	2.69	2.15	0.72	0.49	2.52
Interest & Investment Income	4.58	5.77	4.58	0.22	0.01	0.27	1.20	0.24	0.06	–
Other Non-Operating Income	7.73	-0.74	6.43	-6.27	-3.57	-2.11	-1.10	-4.20	0.25	1.37
Merger & Restructuring Charges	7.01	0.86	–	–	–	–	–	2.00	–	–
Asset Impairment Charges	–	–	0	0	9.76	0	0	–	–	–
Pretax Income	-79	-37	-101	-94	-89	-62	-53	-33	-22	-23
Income Tax Expense	0.04	0.31	0.08	0.03	0.02	0.15	0	0	–	–
Net Income incl. Noncontrolling Interests	–	-37	-101	-94	-89	-62	-53	-33	-22	–
Net Income	-79	-37	-101	-94	-89	-62	-53	-33	-22	-23
Net Income to Common	–	-37	-101	-96	-103	-62	-53	-36	-25	-23
EPS (Basic)(per share)	-1.87	-5.59	-17.07	-45.60	-119.70	-92.70	-138.90	-2,374.50	-1,637.40	-41,654.70
EPS (Diluted)(per share)	-1.87	-5.59	-17.07	-45.60	-119.70	-92.70	-138.90	-2,374.50	-1,637.40	-41,654.70
Shares Outstanding (Basic, Weighted)(shares)	42	6.70	5.93	2.12	0.86	0.67	0.38	0.02	0.02	0.00
Shares Outstanding (Diluted, Weighted)(shares)	42	6.70	5.93	2.12	0.86	0.67	0.38	0.02	0.02	0.00
EBITDA	-86	-36	-107	-87	-85	-60	-52	-29	-22	-24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 66.2%
Operating margin: -1014.4%
Net margin: -1040.1%
Return on equity, FY2025: -76.0%

Financial strength

Current ratio: 11.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1007.4%

Valuation

P/E ratio: –
Price to sales: 40.09
Price to book: 2.24
Dividend yield: –